{"schema_version":"secwatch.filing_event.v1","accession":"0001999480-26-000001","form_type":"8-K","ticker":"ANRO","cik":"0001999480","company_name":"Alto Neuroscience, Inc.","filed_at":"2026-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.962843+00:00","generated_at":"2026-05-15T11:58:46.086024+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Alto Neuroscience reports FY2025 net loss $63.2M; cash $177M; ALTO-207 Phase 2b on track for 1H 2026","bullets":["Cash, cash equivalents & restricted cash $177M as of Dec 31, 2025; runway into 2028 covers four key readouts.","Net loss of $63.2M for FY2025 vs $61.4M in FY2024; R&D expenses $45.6M, G&A $20.7M.","Acquired ALTO-207 (pramipexole/ondansetron) for TRD; Lancet-published PAX-D study showed Cohen's d=0.87 effect size.","ALTO-207 Phase 2b trial expected to start 1H 2026, topline data 2H 2027; $50M PIPE completed in October 2025.","ALTO-101 granted FDA Fast Track for CIAS; Phase 2 POC topline data expected around end of Q1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001999480-26-000001","json":"https://secwatch.observer/filing/0001999480-26-000001.json","markdown":"https://secwatch.observer/filing/0001999480-26-000001.md","text":"https://secwatch.observer/filing/0001999480-26-000001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/0001999480-26-000001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/alto-20260316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:58:46.086024+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7a4d6e7975659e3c548b2aefe04d44e68094407f","claim":"Alto Neuroscience, Inc. reported financial results for full year ended December 31, 2025.","evidence_excerpt":"On March 16, 2026, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal year ended December 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/0001999480-26-000001-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}